Table 4 Analysis of the impact of immunotherapy sequence on patient prognosis.

From: Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

Index

N

OS rate (%)

X2

P

PFS rate (%)

X2

P

1 year

2 year

3 year

1 year

2 year

3 year

Immunotherapy sequence

    

10.501

0.005

   

7.045

0.030

Group 1: ICIs after CRT

30

100.0

79.2

69.1

  

73.3

39.7

36.1

  

Group 2: CRT contemporaneous ICIs

29

65.2

39.8

39.8

  

51.3

11.0

11.0

  

Group 3:CRT after ICIs

20

95.0

70.4

60.3

  

62.6

50.0

37.9

  
  1. OS Overall survival, PFS progression free survival, CRT chemoradiotherapy, ICIs immune checkpoint inhibitors.
Back to article page